Marksans Pharma Limited

Symbol: MARKSANS.NS

NSE

162.85

INR

Market price today

  • 23.2549

    P/E Ratio

  • 0.8305

    PEG Ratio

  • 73.80B

    MRK Cap

  • 0.00%

    DIV Yield

Marksans Pharma Limited (MARKSANS-NS) Stock Price & Analysis

Shares Outstanding

453.16M

Gross Profit Margin

0.52%

Operating Profit Margin

0.20%

Net Profit Margin

0.15%

Return on Assets

0.00%

Return on Equity

0.24%

Return on Capital Employed

0.00%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Mark B. Saldanha
Full-time employees:852
City:Mumbai
Address:Grandeur
IPO:2002-07-19
CIK:

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

General Outlook

In simple terms, Marksans Pharma Limited has 453.164 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.519% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.203%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.151%. This tells us they're good at keeping money after all costs.

Return on Investments

Marksans Pharma Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.236%.

Stock Prices

Marksans Pharma Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $159, while its low point bottomed out at $152. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Marksans Pharma Limited's stock market.

Profitability Ratios

MARKSANS.NS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 20.32% underscores its earnings before tax deductions. The effective tax rate stands at 25.14%, revealing its tax efficiency. The net income per EBT, 74.25%, and the EBT per EBIT, 100.30%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 20.26%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin20.32%
Effective Tax Rate25.14%
Net Income per EBT74.25%
EBT per EBIT100.30%
EBIT per Revenue20.26%

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 2.96, and free cash flow per share, 2.96, depict cash generation on a per-share basis. Lastly, the operating cash flow sales ratio, 0.06, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share2.96
Free Cash Flow per Share2.96
Operating Cash Flow Sales Ratio0.06
Free Cash Flow to Operating Cash Flow Ratio1.00

Debt and Leverage Ratios

An interest coverage of 48.41 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Interest Coverage48.41

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 25.13%, indicates top-line expansion, while the gross profit growth, 27.14%, reveals profitability trends. EBIT growth, 34.39%, and operating income growth, 34.39%, offer insights into operational profitability progression. The net income growth, 44.29%, showcases bottom-line expansion, and the EPS growth, 42.13%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth25.13%
Gross Profit Growth27.14%
EBIT Growth34.39%
Operating Income Growth34.39%
Net Income Growth44.29%
EPS Growth42.13%
EPS Diluted Growth42.13%
Weighted Average Shares Growth1.49%
Weighted Average Shares Diluted Growth1.49%
Dividends per Share Growth-5.30%
Operating Cash Flow Growth139.19%
Free Cash Flow Growth247.23%
10-Year Revenue Growth per Share291.85%
5-Year Revenue Growth per Share99.96%
3-Year Revenue Growth per Share61.60%
10-Year Operating CF Growth per Share471.09%
5-Year Operating CF Growth per Share297.03%
3-Year Operating CF Growth per Share11.43%
10-Year Net Income Growth per Share438.35%
5-Year Net Income Growth per Share696.62%
3-Year Net Income Growth per Share117.31%
10-Year Shareholders Equity Growth per Share1771.83%
5-Year Shareholders Equity Growth per Share265.20%
3-Year Shareholders Equity Growth per Share170.37%
10-Year Dividend per Share Growth per Share101.63%
5-Year Dividend per Share Growth per Share306.87%
3-Year Dividend per Share Growth per Share-66.03%
Receivables Growth1.75%
Inventory Growth14.21%
Asset Growth33.55%
Book Value per Share Growth43.03%
Debt Growth10.98%
R&D Expense Growth-17.46%
SGA Expenses Growth44.66%

Valuation Ratios

The price to sales ratio, 3.51, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 54.94, and price to operating cash flows, 54.94, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price to Sales Ratio3.51
Price Cash Flow Ratio54.94
Price Earnings to Growth Ratio0.83
Enterprise Value Multiple14.66
Price to Operating Cash Flow Ratio54.94
Price to Free Cash Flows Ratio54.94
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Marksans Pharma Limited (MARKSANS.NS) on the NSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 23.255 in 2024.

What is the ticker symbol of Marksans Pharma Limited stock?

The ticker symbol of Marksans Pharma Limited stock is MARKSANS.NS.

What is company IPO date?

IPO date of Marksans Pharma Limited is 2002-07-19.

What is company current share price?

Current share price is 162.850 INR.

What is stock market cap today?

The market cap of stock today is 73797757400.000.

What is PEG ratio in 2024?

The current 0.831 is 0.831 in 2024.

What is the number of employees in 2024?

In 2024 the company has 852.